A retrospective observational study of investigating the real world data of post-treatment after drug-induced lung injury by osimertinib and the safety and efficacy of EGFR-TKI re-challenge

A retrospective observational study of investigating the real world data of post-treatment after drug-induced lung injury by osimertinib and the safety and efficacy of EGFR-TKI re-challenge - Osi-risk study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044854

Enrollment

250

Registered

2021-07-13

Start date

2021-06-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non small cell lung cancer patients who received Osimertinib as first-line therapy and who experienced clinical drug-induced lung injury

Exclusion criteria

Exclusion criteria: Patients participating in studies aimed at similar analysis of treatment after Osimertinib

Design outcomes

Primary

Measure	Time frame
Cumulative incidence of drug-induced lung injury at 3, 6, and 12 months after initiation of EGFR-TKI rechallenge	—

Countries

Japan

Contacts

Public ContactNaoya Nishioka

Shizuoka cancer center Thoracic Oncology

n.nishioka@scchr.jp055-989-5222

Outcome results